Cargando…

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease

There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson’s disease (PD) for over 20 years in various clinical trials....

Descripción completa

Detalles Bibliográficos
Autores principales:	Teo, Kay Cheong, Ho, Shu-Leong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847108/ https://www.ncbi.nlm.nih.gov/pubmed/24011391 http://dx.doi.org/10.1186/2047-9158-2-19

Ejemplares similares

Monoamine Oxidase Inhibitory Constituents of Propolis: Kinetics and Mechanism of Inhibition of Recombinant Human MAO-A and MAO-B
por: Chaurasiya, Narayan D., et al.
Publicado: (2014)

Monoamine oxidase A (MAO A) inhibitors decrease glioma progression
por: Kushal, Swati, et al.
Publicado: (2016)

Molecular docking analysis and dynamics simulation of salbutamol with the monoamine oxidase B (MAO-B) enzyme
por: Abdulhameed Odhar, Hasanain, et al.
Publicado: (2022)

Three Dimensional Pharmacophore Modelling of Monoamine oxidase-A (MAO-A) inhibitors
por: Sairam, Kalapatapu V.V.M., et al.
Publicado: (2007)

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
por: Tan, Yu-Yan, et al.
Publicado: (2022)

Marine natural products with monoamine oxidase (MAO) inhibitory activity
por: Hong, Ahreum, et al.
Publicado: (2020)

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
por: Robottom, Bradley J
Publicado: (2011)

β-Carboline Alkaloids in Soy Sauce and Inhibition of Monoamine Oxidase (MAO)
por: Herraiz, Tomás
Publicado: (2023)

Rethinking, reducing, and refining the classical oral tyramine challenge test of monoamine oxidase (MAO) inhibitors
por: van Hoogdalem, Ewoud‐Jan, et al.
Publicado: (2023)

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
por: Alborghetti, Marika, et al.
Publicado: (2019)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis
por: Yeung, Andy Wai Kan, et al.
Publicado: (2019)

Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
por: Aljanabi, Reem, et al.
Publicado: (2021)

Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action
por: Rinaldi, Domiziana, et al.
Publicado: (2023)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
por: Chiuccariello, Lina, et al.
Publicado: (2015)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration
por: Tzvetkov, Nikolay T., et al.
Publicado: (2017)

Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022)

From warrior genes to translational solutions: novel insights into monoamine oxidases (MAOs) and aggression
por: Mentis, Alexios-Fotios A., et al.
Publicado: (2021)

Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors
por: Kaya, Betül, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Novel N-Pyridyl-Hydrazone Derivatives as Potential Monoamine Oxidase (MAO) Inhibitors
por: Turan-Zitouni, Gülhan, et al.
Publicado: (2018)

Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson’s disease
por: Krishna, Rakhee, et al.
Publicado: (2014)

Simultaneous engineering of an enzyme's entrance tunnel and active site: the case of monoamine oxidase MAO-N
por: Li, Guangyue, et al.
Publicado: (2017)

Correction: From warrior genes to translational solutions: novel insights into monoamine oxidases (MAOs) and aggression
por: Mentis, Alexios-Fotios A., et al.
Publicado: (2021)

Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
por: Löhle, Matthias, et al.
Publicado: (2011)

The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: meta-analysis of randomized controlled trials
por: Huang, Yao Hsien, et al.
Publicado: (2021)

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease
por: Zou, Dajiang, et al.
Publicado: (2023)

Correction: Simultaneous engineering of an enzyme’s entrance tunnel and active site: the case of monoamine oxidase MAO-N
por: Li, Guangyue, et al.
Publicado: (2017)

Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease
por: Lieu, Christopher A., et al.
Publicado: (2013)

ABUSE OF MONOAMINE OXIDASE INHIBITORS
por: Ananth, Jambur, et al.
Publicado: (1995)

Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors
por: Zarmouh, Najla O., et al.
Publicado: (2016)

Halogenated Coumarin–Chalcones as Multifunctional Monoamine Oxidase-B and Butyrylcholinesterase Inhibitors
por: Rehuman, Nisha Abdul, et al.
Publicado: (2021)

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
por: Alborghetti, Marika, et al.
Publicado: (2023)

Monoamine Oxidase B in Renal Cell Carcinoma
por: Hodorová, Ingrid, et al.
Publicado: (2018)

Monoamine Reuptake Inhibitors in Parkinson's Disease
por: Huot, Philippe, et al.
Publicado: (2015)

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type‐B inhibitor: A Cross‐Sectional, Cohort Study
por: Dashtipour, Khashayar, et al.
Publicado: (2015)

Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis
por: Binde, Caroline D., et al.
Publicado: (2020)

A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
por: Margret, A. Anita, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sastcsnbj1rdqaf6hbg32v0tcs